MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 593037 | Name: Atomoxetine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Atomoxetine is a norepinephrine reuptake inhibitor approved for the treatment of attention deficit hyperactivity disorder (ADHD). The brand name is Strattera. The initial therapeutic effects of atomoxetine usually take 2–4 weeks to become apparent. There has been some suggestion that atomoxetine might be a helpful adjunct in people with major depression, especially in cases where ADHD occurs comorbidly to major depression.

Chemical Structure

Atomoxetine
Atomoxetine
CAS#83015-26-3 (free base)

Theoretical Analysis

MedKoo Cat#: 593037

Name: Atomoxetine

CAS#: 83015-26-3 (free base)

Chemical Formula: C17H21NO

Exact Mass: 255.1623

Molecular Weight: 255.36

Elemental Analysis: C, 79.96; H, 8.29; N, 5.49; O, 6.27

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
83015-26-3 (free base) 82248-59-7 (HCl)
Synonym
Atomoxetine; HSDB 7352; HSDB-7352; HSDB7352
IUPAC/Chemical Name
Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, (gammaR)-
InChi Key
VHGCDTVCOLNTBX-QGZVFWFLSA-N
InChi Code
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
SMILES Code
CC1=CC=CC=C1O[C@@H](C2=CC=CC=C2)CCNC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 255.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S. Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study. J Clin Psychopharmacol. 2018 Aug 10. doi: 10.1097/JCP.0000000000000939. [Epub ahead of print] PubMed PMID: 30102629. 2: Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Aug 7. pii: S2215-0366(18)30269-4. doi: 10.1016/S2215-0366(18)30269-4. [Epub ahead of print] PubMed PMID: 30097390. 3: Froehlich T, Fogler J, Barbaresi WJ, Elsayed NA, Evans SW, Chan E. Using ADHD Medications to Treat Coexisting ADHD and Reading Disorders: A Systematic Review. Clin Pharmacol Ther. 2018 Jul 27. doi: 10.1002/cpt.1192. [Epub ahead of print] Review. PubMed PMID: 30053315. 4: van den Brink RL, Nieuwenhuis S, Donner TH. Amplification and Suppression of Distinct Brain-wide Activity Patterns by Catecholamines. J Neurosci. 2018 Jul 23. pii: 0514-18. doi: 10.1523/JNEUROSCI.0514-18.2018. [Epub ahead of print] PubMed PMID: 30037827. 5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501732/ PubMed PMID: 30000791. 6: Biaggioni I. Orthostatic Hypotension in the Hypertensive Patient. Am J Hypertens. 2018 Jul 2. doi: 10.1093/ajh/hpy089. [Epub ahead of print] PubMed PMID: 29982276. 7: Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990. doi: 10.1002/14651858.CD007990.pub3. Review. PubMed PMID: 29944175. 8: Kweon K, Yoon JS, Park KJ, Kim SO, Choi JH, Kim HW. Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review. Psychiatry Investig. 2018 Jun;15(6):649-654. doi: 10.30773/pi.2018.02.25.1. Epub 2018 Jun 21. PubMed PMID: 29940719; PubMed Central PMCID: PMC6018137. 9: Edvinsson D, Ekselius L. Long-Term Tolerability and Safety of Pharmacological Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A 6-Year Prospective Naturalistic Study. J Clin Psychopharmacol. 2018 Aug;38(4):370-375. doi: 10.1097/JCP.0000000000000917. PubMed PMID: 29927781; PubMed Central PMCID: PMC6039396. 10: Naguy A, Alamiri B, El-Sori DS, Khraibut B. Methylphenidate-Associated Onychotillomania, Myoclonus, and Enuresis Reversed by Switching to Atomoxetine. Am J Ther. 2018 Jun 18. doi: 10.1097/MJT.0000000000000812. [Epub ahead of print] PubMed PMID: 29927775. 11: Yonezawa K, Nonaka S, Iwakura Y, Kusano Y, Funamoto Y, Kanchi N, Yamaguchi N, Kusumoto Y, Imamura A, Ozawa H. Investigation into the plasma concentration of ω3 polyunsaturated fatty acids in Japanese attention-deficit hyperactivity disorder patients. J Neural Transm (Vienna). 2018 Jun 20. doi: 10.1007/s00702-018-1895-z. [Epub ahead of print] PubMed PMID: 29926268. 12: Frampton JE. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD. Drugs. 2018 Jul;78(10):1025-1036. doi: 10.1007/s40265-018-0936-0. PubMed PMID: 29923015. 13: Moreira-Maia CR, Massuti R, Tessari L, Campani F, Akutagava-Martins GC, Cortese S, Rohde LA. Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2018 Jun;97(24):e10923. doi: 10.1097/MD.0000000000010923. Review. PubMed PMID: 29901582; PubMed Central PMCID: PMC6023876. 14: Pozzi M, Carnovale C, Peeters GGAM, Gentili M, Antoniazzi S, Radice S, Clementi E, Nobile M. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis. J Affect Disord. 2018 Oct 1;238:161-178. doi: 10.1016/j.jad.2018.05.021. Epub 2018 May 22. Review. PubMed PMID: 29883938. 15: Coppola M, Mondola R. Impulsivity in Alcohol-Dependent Patients with and without ADHD: The Role of Atomoxetine. J Psychoactive Drugs. 2018 Jun 7:1-6. doi: 10.1080/02791072.2018.1471247. [Epub ahead of print] PubMed PMID: 29877779. 16: Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, Fujita J, Iida J. Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol Psychiatr Sci. 2018 May 28:1-5. doi: 10.1017/S2045796018000252. [Epub ahead of print] PubMed PMID: 29804548. 17: Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. Am J Ther. 2018 May 16. doi: 10.1097/MJT.0000000000000785. [Epub ahead of print] PubMed PMID: 29782344. 18: Ghorbani M, Chamsaz M, Aghamohammadhasan M, Shams A. Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin-norepinephrine reuptake inhibitor drugs. Anal Biochem. 2018 Jun 15;551:7-18. doi: 10.1016/j.ab.2018.05.003. Epub 2018 May 8. PubMed PMID: 29750941. 19: Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, Hyman SL, Hollway J, Lecavalier L, Page K, Rice R Jr. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):322-330. doi: 10.1089/cap.2017.0134. Epub 2018 Apr 25. PubMed PMID: 29694241; PubMed Central PMCID: PMC5994674. 20: Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018 Feb;30(1):78-95. doi: 10.1080/09540261.2018.1458706. Epub 2018 Apr 25. PubMed PMID: 29693461.